ライフサイエンスコーパス: B virus

1 n immunodeficiency virus (HIV) and hepatitis B virus.

2 er challenge with a lethal dose of influenza B virus.

3 nalcoholic fatty liver disease and hepatitis B virus.

4 ing in children infected with influenza A or B virus.

5 a hepadnavirus closely related to hepatitis B virus.

6 ent resurgence of epidemics due to influenza B virus.

7 cation, and pathogenesis for influenza A and B viruses.

8 n some neutralization breadth within subtype B viruses.

9 us, a type A:H3N2 virus, and one or two type B viruses.

10 d 53% (95% CI, 43% to 61%) against influenza B viruses.

11 assay and microneutralisation for influenza B viruses.

12 antibodies that broadly recognize influenza B viruses.

13 ctive against influenza A(H3N2) viruses than B viruses.

14 y 1% of the samples contained both RSV A and B viruses.

15 presentative strains of both influenza A and B viruses.

16 tion were 2% for A/H1N1 and 1% for A/H3N2and B viruses.

17 were 5% for A/H1N1, 4% for A/H3, and 3% for B viruses.

18 and AMC011 trimers, all derived from subtype B viruses.

19 ions and infections with A/H1N1, A/H3N2, and B viruses.

20 ibility differ between influenza A(H3N2) and B viruses.

21 ther chronic liver diseases due to hepatitis B virus (12.2 million) and hepatitis C virus (10.4 milli

22 in 107 samples (Flu A virus, 73 samples; Flu B virus, 36 samples; dual Flu A/B virus positive, 2 samp

23 ed 112 samples (Flu A virus, 76 samples; Flu B virus, 36 samples; invalid rate, 6/201 [3.0%]).

24 ed 102 samples (Flu A virus, 69 samples; Flu B virus, 37 samples; dual Flu A/B virus positive, 4 samp

25 ed 112 samples (Flu A virus, 74 samples; Flu B virus, 38 samples; invalid rate, 11/201 [5.5%]), and t

26 eritor antigen test (Flu A virus, 79.5%; Flu B virus, 66.7%).

27 10.4 million), liver cancer due to hepatitis B virus (9.4 million), rheumatic heart disease due to st

28 s adaptive responses as opposed to hepatitis B virus and cancer-testis antigens.

29 The study of hepatitis B virus and development of curative antivirals are hampe

30 The prevalence of viral hepatitis (hepatitis B virus and hepatitis C virus) in migrants is higher tha

31 We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL)

32 pregulation of Gal-9 on T cells in hepatitis B virus and HPV infections.

33 eries of contemporary genotypes of hepatitis B virus and parvovirus B19 in ancient human remains demo

34 oronavirus, human metapneumovirus, influenza B virus and respiratory syncytial virus.

35 monkey virus), two hepadnaviruses (hepatitis B virus and woodchuck hepatitis virus), and an intron-re

36 is a significant barrier for several lineage B viruses and that bypassing this barrier allows several

37 rent strains and subtypes of influenza A and B viruses and to demonstrate how these data can provide

38 % for influenza A virus, 98.0% for influenza B virus, and 97.7% for RSV.

39 ffect replication of retroviruses, hepatitis B virus, and hepatitis C virus (HCV).

40 targets, i.e., hepatitis C virus, hepatitis B virus, and human immunodeficiency virus 1.

41 sm of action of broadly protective influenza B virus antibodies is required to inform vaccine develop

42 nza A, human immunodeficiency, and hepatitis B viruses are examined in the first section; then the se

43 ivalent LAIV (containing A/H1N1, A/H3N2, and B viruses) at days 3, 7, and 14 before tonsillectomy.

44 k of environmental transmission of hepatitis B virus but also open up the possibility of testing othe

45 sposons, and other viruses such as hepatitis B virus, but can cause a mutator phenotype in many cance

46 fects on in vitro fitness of influenza A and B viruses, but the ability of these viruses to transmit

47 Macacine herpesvirus or B Virus (BV) is a zoonotic agent that leads to high mort

48 We also demonstrate how different lineage B viruses can recombine to gain entry into human cells,

49 is likely that the closely related hepatitis B virus capsid protein undergoes similar structural chan

50 Influenza B viruses cause seasonal epidemics and are a considerabl

51 Influenza A and B viruses cause seasonal flu epidemics.

52 nged suppression of human and duck hepatitis B virus cccDNA transcription, which is associated with t

53 Conversely, in 2011-2012, during which B viruses circulated, and in 2013-2014, when A/H1N1 circ

54 HLA-B*5701-negative adults without hepatitis B virus co-infection to receive coformulated bictegravir

55 za A subtypes, A(H1N1) and A(H3N2), and type B viruses co-circulate in humans and infection with one

56 a human immunodeficiency virus or hepatitis B virus coinfection, and those treated with both PEG/RBV

57 r, smoking status, hepatitis C and hepatitis B virus coinfection, group of exposure, nadir CD4 count,

58 ed with a similar modest change in hepatitis B virus core antigen polypeptide (HBcAg/p21) synthesis,

59 biomarkers toward better defining hepatitis B virus cure should occur in parallel with development o

60 Coxsackie-B-viruses (CVB) are frequent causes of acute myocarditis

61 high load of nontarget template or influenza B virus, demonstrating assay specificity.

62 The hepatitis B virus deploys the hepatitis B virus X protein (HBx) as

63 93.2%, 100%, and 100%, respectively) and Flu B virus detection (97.2%, 94.4%, and 91.7%, respectively

64 The specificity for Flu A and B virus detection by all methods was >97%.

65 Serum qHBcrAg, qAnti-HBc, and hepatitis B virus DNA were obtained at TDF initiation and every 6-

66 onse after hepatitis C, suppressed hepatitis B virus during treatment, and alcoholic and nonalcoholic

67 has been lower than against A(H1N1)pdm09 and B viruses, even when circulating viruses remained antige

68 Influenza B virus evolves more slowly than influenza A virus, but

69 management for occupational HIV or hepatitis B virus exposures includes postexposure prophylaxis (PEP

70 Of note, we rescued recombinant influenza B viruses expressing mosaic B hemagglutinins, which coul

71 ansmission, while 38F-containing A(H3N2) and B viruses failed to transmit via the airborne route.

72 circulation of 3 or more distinct influenza B viruses, further complicating influenza vaccine formul

73 thylation events in the integrated hepatitis B virus genome.

74 By analyzing over 12,000 influenza B virus genomes, we describe the processes enabling the

75 fected with A/H1N1pdm09, A/H3N2 or influenza B virus had prolonged viral RNA shedding (+/-1-2 days) c

76 In Asia, HCCs from patients with hepatitis B virus have been efficiently converted into PDXs, but f

77 Influenza B viruses have circulated in humans for over 80 y, causi

78 ded 230 million people living with hepatitis B virus (HBV) and 52 million people living with hepatiti

79 Hepatitis B virus (HBV) and hepatitis C virus (HCV) cause 1.3 mill

80 Hepatitis B virus (HBV) and hepatitis C virus (HCV) remain, at pre

81 ve mixed tailing in transcripts of hepatitis B virus (HBV) and human cytomegalovirus (HCMV), generate

82 such as Epstein-Barr virus (EBV), hepatitis B virus (HBV) and human papilloma virus (HPV; for exampl

83 Patients co-infected with hepatitis B virus (HBV) and the human immunodeficiency virus (HIV)

84 displays excellent potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV).

85 ls of assembly/release pathways of hepatitis B virus (HBV) are still unknown.

86 etect the presence and activity of hepatitis B virus (HBV) are the cornerstones of diagnosis and mana

87 Hepatitis B virus (HBV) can transmit through needle sharing.

88 by monitoring the assembly of the hepatitis B virus (HBV) capsid.

89 alyze in real time the assembly of Hepatitis B Virus (HBV) capsids below the pseudocritical concentra

90 The hepatitis B virus (HBV) causes acute and chronic liver infection,

91 Hepatitis B virus (HBV) causes chronic infection in an estimated 2

92 Hepatitis B virus (HBV) chronic infection affects up to 240 millio

93 Hepatitis B virus (HBV) chronically infects 250 million people wor

94 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based

95 direct-acting antivirals (DAAs) in hepatitis B virus (HBV) coinfection can result in HBV reactivation

96 hotropic virus type 1 (HTLV-1) and hepatitis B virus (HBV) coinfection is high in certain Indigenous

97 infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral therapy (ART

98 stics and comorbidities to chronic hepatitis B virus (HBV) controls using propensity scores.

99 ts, their lack of activity against hepatitis B virus (HBV) could limit their global impact, particula

100 re involved in the biosynthesis of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, we d

101 Hepatitis B virus (HBV) covalently closed circular (ccc)DNA is the

102 The biosynthesis of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) re

103 face antigen (HBsAg)-positive with hepatitis B virus (HBV) DNA concentration of less than 29 IU/mL, a

104 ntigen, antibodies to hepatitis D, hepatitis B virus (HBV) DNA for hepatitis B surface antigen (HBsAg

105 EC deaminases as enzymes targeting hepatitis B virus (HBV) DNA in the nucleus thus affecting its pers

106 The paucity of hepatitis B virus (HBV) DNA measurement in low-/middle-income coun

107 %, 100%, and 100% had undetectable hepatitis B virus (HBV) DNA, respectively.

108 The management of hepatitis B virus (HBV) e antigen-positive viremic patients with n

109 Hepatitis B virus (HBV) encodes a multifunction reverse transcript

110 e examined factors associated with hepatitis B virus (HBV) exposure among people who reported ever us

111 DNA) is the persistent form of the hepatitis B virus (HBV) genome in viral infection and an undispute

112 nflicting data exist as to whether hepatitis B virus (HBV) has the ability to induce innate immune re

113 93 European and African shrews for hepatitis B virus (HBV) homologs to elucidate the enigmatic geneal

114 The basis for the persistence of hepatitis B virus (HBV) in hepatocytes, even in the presence of av

115 for replication and persistence of hepatitis B virus (HBV) in the chronically infected liver.

116 blishment of a seronegative occult hepatitis B virus (HBV) infection (OBI) in a successfully vaccinat

117 Hepatitis B virus (HBV) infection affects approximately 300 millio

118 iduals can naturally clear chronic hepatitis B virus (HBV) infection and acquire protection from rein

119 novel mechanisms of action against hepatitis B virus (HBV) infection are being explored with the goal

120 Therapies for chronic hepatitis B virus (HBV) infection are urgently needed because of v

121 SPSTF) found antiviral therapy for hepatitis B virus (HBV) infection associated with improved interme

122 sm of host immune defenses against hepatitis B virus (HBV) infection by the viral proteins is specula

123 Hepatitis B virus (HBV) infection can be prevented through vaccina

124 ed therapeutic ARC-520 for chronic hepatitis B virus (HBV) infection consists of a melittin-derived p

125 to IFN therapy.IMPORTANCE Chronic hepatitis B virus (HBV) infection continues to be a major global h

126 o tackle the huge global burden of hepatitis B virus (HBV) infection depends on improved insights int

127 Screening for hepatitis B virus (HBV) infection during pregnancy identifies wome

128 Hepatitis B virus (HBV) infection has a global reach with high pre

129 sm(s) of age-dependent outcomes of hepatitis B virus (HBV) infection in humans, we previously establi

130 d to estimate the global burden of hepatitis B virus (HBV) infection in people living with human immu

131 Chronic hepatitis B virus (HBV) infection is a global public health challe

132 Hepatitis B virus (HBV) infection is a major cause of acute and ch

133 Chronic hepatitis B virus (HBV) infection is a major public health problem

134 Chronic hepatitis B virus (HBV) infection is a risk factor for hepatocellu

135 Hepatitis B virus (HBV) infection persists because the virus-speci

136 Acute hepatitis B virus (HBV) infection remains a frequent cause of acut

137 Hepatitis B virus (HBV) infection remains a major global health pr

138 ldren with immune-tolerant chronic hepatitis B virus (HBV) infection remains unknown.

139 nt Goals (SDGs) for elimination of hepatitis B virus (HBV) infection set ambitious targets for 2030.

140 nal cure) in patients with chronic hepatitis B virus (HBV) infection significantly reduces liver-rela

141 Patients with resolved hepatitis B virus (HBV) infection who are treated for hematologica

142 ion persons worldwide with chronic hepatitis B virus (HBV) infection, a leading causes of liver cance

143 (LTBI), 63.5% were susceptible to hepatitis B virus (HBV) infection, and 31.0% had at least one inte

144 e is no effective cure for chronic hepatitis B virus (HBV) infection, antibodies are protective and c

145 eatment regimen for curing chronic hepatitis B virus (HBV) infection.

146 une-tolerant (IT) phase of chronic hepatitis B virus (HBV) infection.

147 CC), often associated with chronic hepatitis B virus (HBV) infection.

148 with current or prior exposure to hepatitis B virus (HBV) infection.

149 Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections can lead to cirrhosis, end-stag

150 the United States, but changes in hepatitis B virus (HBV) infections have not been studied.

151 al increase in the number of acute hepatitis B virus (HBV) infections in the United States.

152 Chronic hepatitis B virus (HBV) infections result in 887,000 deaths annual

153 Hepatitis B virus (HBV) integration has implications for cancer de

154 -DNA), generated from junctions of hepatitis B virus (HBV) integration in the HCC chromosome, as a ci

155 Hepatitis B virus (HBV) is a leading cause of liver disease.

156 Hepatitis B virus (HBV) is a leading cause of liver failure and he

157 Hepatitis B virus (HBV) is a major global health concern, and the

158 ost proteins on HBV-DNA.IMPORTANCE Hepatitis B virus (HBV) is a major global health concern, chronica

159 Hepatitis B virus (HBV) is a major health problem worldwide, with

160 occurrence as a satellite virus of hepatitis B virus (HBV) is a singular case in animal virology for

161 Hepatitis B virus (HBV) is a unique, tiny, partially double-strand

162 Hepatitis B virus (HBV) is an important but difficult to study hum

163 larly in sub-Saharan Africa, where hepatitis B virus (HBV) is an important risk factor.

164 V) superinfection in patients with hepatitis B virus (HBV) is associated with rapid progression to li

165 Hepatitis B virus (HBV) is the leading cause of hepatocellular car

166 Hepatitis B virus (HBV) is the major causative factor of chronic v

167 pensated cirrhosis associated with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, with

168 ified 35,356 patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections.

169 tions of hepatocytes infected with hepatitis B virus (HBV) or only harboring HBV DNA integrations coe

170 Reports were published recently on hepatitis B virus (HBV) reactivation (HBV-R) in patients with HBV-

171 gue (NA) is recommended to prevent hepatitis B virus (HBV) reactivation in hepatitis B surface antige

172 l component of prophylaxis against hepatitis B virus (HBV) recurrence in liver transplantation (LT) r

173 d Organ failure) for patients with Hepatitis B Virus (HBV) related acute-on-chronic liver failure (AC

174 Hepatitis B virus (HBV) remains a major global health problem with

175 th a yearly death toll of 880,000, hepatitis B virus (HBV) remains a major health problem worldwide,

176 Despite an effective vaccine, hepatitis B virus (HBV) remains a major public health threat since

177 sid assembly modulator that blocks hepatitis B virus (HBV) replication, was well tolerated and demons

178 le in the epigenetic regulation of hepatitis B virus (HBV) replication.

179 We have evaluated the ability of hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (

180 a clinically pragmatic approach to hepatitis B virus (HBV) screening and management.

181 inhibit assembly and secretion of hepatitis B virus (HBV) subviral particles.

182 REP 2139 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg), enhancing the res

183 re active against alphaviruses and hepatitis B virus (HBV) than ZAPS and ZAPM and elucidates the effe

184 Smoking interacts with hepatitis B virus (HBV) to increase the risk of hepatocellular car

185 restriction factor that suppresses hepatitis B virus (HBV) transcription.

186 es 5/6 complex (Smc5/6) suppresses hepatitis B virus (HBV) transcription.

187 of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to guide clinical tria

188 Hepatitis B virus (HBV) X protein, HBx, interacts with anti-apopto

189 Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), nonalcoholic fat

190 r confirmed clonal integrations of hepatitis B virus (HBV), human papillomavirus (HPV), Epstein-Barr

191 Viral hepatitis, and particularly hepatitis B virus (HBV), is an important disease because of its hi

192 pathogens, Schistosoma mansoni and hepatitis B virus (HBV), is barely understood.

193 ents with hepatitis C virus (HCV), hepatitis B virus (HBV), NAFLD, and alcoholic liver diseases; (2)

194 ons by either hepatitis A virus or hepatitis B virus (HBV), or a noninfectious cause for their ALF.

195 ed by prolonged infection with the hepatitis B virus (HBV), which can substantially increase the risk

196 correlated with poor prognosis of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HBV-H

197 Hepatitis B virus (HBV)-encoded X protein (HBx) plays a critical r

198 e and confirm advanced fibrosis in hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infe

199 arcinoma (HCC) is most striking in hepatitis B virus (HBV)-related cases.

200 proteogenomic characterization of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) usi

201 proaches to augment the endogenous hepatitis B virus (HBV)-specific T cell response in CHB patients h

202 the quantitative detection of the hepatitis B virus (HBV)-the major cause of liver cirrhosis and hep

203 activity of AdrA was addressed in hepatitis B virus (HBV)-transgenic and adenovirus-associated virus

204 stages of chronic coinfection with hepatitis B virus (HBV).

205 potential that has been applied to hepatitis B virus (HBV).

206 living with chronic infection with hepatitis B virus (HBV).

207 scriptase (RT) activity of HIV and hepatitis B virus (HBV).

208 /1000 patient-years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.

209 with acute, resolved, and chronic hepatitis B virus (HBV)infection but might also signify occult HBV

210 tection of anti-HCV antibody), and hepatitis B virus (HBV; based on detection of HBV surface antigen)

211 ansmitted infectious agents (TTIs; hepatitis B virus [HBV], HIV, human T-cell lymphotropic virus type

212 Hepatitis B viruses (HBVs), which are enveloped viruses with rever

213 re frequently from older, heavier, hepatitis B virus (HCV)+, and more comorbid donors (P < 0.001).

214 Here, we investigated four influenza B virus hemagglutinin (HA) head specific, hemagglutinati

215 The influenza B virus hemagglutinin contains four major antigenic site

216 s and the noncanonical epitopes of influenza B virus hemagglutinin in animals and humans using novel

217 order to identify residues on the influenza B virus hemagglutinin interacting with the MAbs, we gene

218 utralizing antibodies specific for influenza B virus hemagglutinin.

219 tanding of the mechanisms by which hepatitis B virus, hepatitis C virus, alcohol, fatty liver disease

220 (human immunodeficiency virus-1/2, hepatitis B virus, hepatitis C virus, human T-cell lymphotropic vi

221 y of rhinovirus, adenovirus, influenza A and B viruses, human parainfluenza viruses 1-3 (HPIV), respi

222 leaves influenza A virus (IAV) and influenza B virus (IBV) HA possessing a monobasic cleavage site.

223 Influenza B virus (IBV) infections can cause severe disease in chi

224 Influenza B virus (IBV) is an acute, respiratory RNA virus that ha

225 dapted influenza A virus (IAV) and influenza B virus (IBV) replication in human cells.

226 Influenza B virus (IBV) undergoes seasonal antigenic drift more sl

227 za A virus (IAV), group 2 IAV, and influenza B virus (IBV) were designed and produced in bacterial re

228 ive for influenza A virus (IAV) or influenza B virus (IBV).

229 ANCE Influenza A viruses (IAV) and influenza B viruses (IBV) cause significant morbidity and mortalit

230 ld induce broad protection against influenza B viruses.IMPORTANCE While broadly protective antibodies

231 ed, the CDC Flu A/B PCR assay detected Flu A/B virus in 107 samples (Flu A virus, 73 samples; Flu B v

232 s of the failed immune response to hepatitis B virus in patients with chronic infection.

233 s confirmed in HEV gt1, but not in Hepatitis B Virus infected animals.

234 ion people are living with chronic hepatitis B virus infection (CHB), and the development of novel cu

235 ectional analysis of prevalence of hepatitis B virus infection (HBV) among rural couples was conducte

236 g low fruit intake (14 provinces), hepatitis B virus infection (seven provinces), smoking (six provin

237 a useful tool to treat or prevent influenza B virus infection in pediatric cohorts or in a therapeut

238 titis B vaccine birth dose and the hepatitis B virus infection rate was 4 times lower.

239 everal disease outcomes, including hepatitis B virus infection(5-7), graft-versus-host disease(8) and

240 HLA-B*5701 negative, did not have hepatitis B virus infection, and had an estimated glomerular filtr

241 ol, immunizing populations against hepatitis B virus infection, and screening for colorectal cancer.

242 sfunction in patients with chronic hepatitis B virus infection, immunotherapy strategies in developme

243 Among individuals with hepatitis B virus infection, liver-related mortality decreased ste

244 due to influenza A(H1N1)pdm09 and influenza B virus infection, respectively.

245 immunity in patients with chronic hepatitis B virus infection.

246 at occurs only in patients with an hepatitis B virus infection.

247 .01; immunology, P = 0.02) but not influenza B virus infection.

248 Fewer than 1% of chronic hepatitis B virus infections per year are cured with antiviral tre

249 Influenza A or B virus infections were detected in 598/1030 (58%) of th

250 ents that are mounted during influenza A and B virus infections, as well as during viral innate immun

251 pproved in 2018 for treating influenza A and B virus infections.

252 isease), and hepatitis C virus and hepatitis B virus infections.

253 For the discovery of hepatitis B virus integration sites from probe capture data, the v

254 Influenza B virus is a serious health concern for children, in par

255 ity of these antibodies recognized influenza B viruses isolated over the period of 73 years and bind

256 argeting peptides derived from the hepatitis B virus large envelope protein (HBVpreS) to specifically

257 The tetrameric influenza A and B virus M2 proteins form canonical proton channels that

258 n = 5], and parechovirus [n = 2]), hepatitis B virus (n = 10), cytomegalovirus (n = 9), Epstein-Barr

259 positive viral detections included hepatitis B virus (n = 2), human pegivirus 1 (n = 2), Epstein-Barr

260 readth to multiple different influenza A and B virus neuraminidases.

261 eased risk of HCC in patients with hepatitis B virus or adeno-associated virus type 2 infection might

262 (HCCs) from patients infected with hepatitis B virus or adeno-associated virus type 2, due to integra

263 fluenza A(H1N1)pdm09 (p=0.01), and influenza B viruses (p=0.04).

264 We found that influenza B virus populations have lower within-host genetic diver

265 samples; Flu B virus, 36 samples; dual Flu A/B virus positive, 2 samples), while the ID Now virus det

266 samples; Flu B virus, 37 samples; dual Flu A/B virus positive, 4 samples; invalid rate, 1/201 [0.5%])

267 and 13.4% had past infection with hepatitis B virus (positive anti-HBcore).

268 Annual vaccination against influenza A and B viruses promotes the induction of Abs and memory B cel

269 Hepatitis B virus reactivation, defined as an abrupt increase in H

270 son disease, Budd-Chiari syndrome, hepatitis B virus reactivation, inborn errors of metabolism.

271 y, age-standardized mortality from hepatitis B virus-related extrahepatic complications increased by

272 d how the within-host diversity of influenza B virus relates to its global evolution by sequencing vi

273 and ANP32B are essential for influenza A and B virus replication, such that in their absence cells be

274 irus(RV-C)microbiome(mixed)T2(low); endotype B, virus(RV-A)microbiome(Haemophilus)T2(low); endotype C

275 The Env derived from B41, a subtype B virus, shares a glycan hole centered on positions 230

276 of T cells engineered to express a hepatitis B virus-specific (HBV-specific) T cell receptor (TCR) ma

277 t both homologous and heterologous influenza B virus strains in the mouse model.

278 0(8) particles/mL was obtained for hepatitis B virus T = 4 capsids with a 1.3 muL sample.

279 e and greater lifetime exposure to hepatitis B virus than US-born women.

280 elta virus (HDV) is a satellite of hepatitis B virus that increases the severity of acute and chronic

281 elta virus (HDV) is a satellite of hepatitis B virus that increases the severity of liver disease; ap

282 nt mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF

283 ypassing this barrier allows several lineage B viruses to enter human cells through an unknown recept

284 rls-only HPV16/18 vaccination, and hepatitis B virus vaccination arms.

285 study, we report a novel universal influenza B virus vaccination strategy based on "mosaic" hemagglut

286 ANCE This work reports a universal influenza B virus vaccination strategy based on focusing antibody

287 a universal or broadly protective influenza B virus vaccine lags behind the development of such a va

288 evelopment toward a more effective influenza B virus vaccine.

289 serve as the basis for a universal influenza B virus vaccine.IMPORTANCE This work reports a universal

290 virus, 3.0 [95% CI, 1.8-5.0]), but influenza B virus was not (RR, 1.8; 95% CI, .7-4.6).

291 ing in children infected with influenza A or B virus was studied.

292 (1054 [84%] of 1251 patients), and hepatitis B virus was the leading cause in the other African count

293 ersion to at least one of the influenza A or B viruses was observed among 196 (77%) of 254 influenza-

294 Conversely, children infected with influenza B viruses were more likely than adults to show NA-only s

295 against influenza A(H1N1)pdm09, A(H3N2), and B viruses were similar among statin users and nonusers.

296 Other STIs, except hepatitis B virus, were also more prevalent among HIV-infected MSM

297 trains, and both were found against H3N2 and B viruses, whereas only systemic responses were observed

298 we used modified hemagglutinins of influenza B virus which display only one or none of the major anti

299 The hepatitis B virus deploys the hepatitis B virus X protein (HBx) as a suppressor of host defenses

300 peutic targeting of HBx.IMPORTANCE Hepatitis B virus X protein (HBx) is a promising drug target since